NCT06626737

Dapagliflozin in Allo-HCT for aGVHD

Dapagliflozin for Preventing Acute Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation: A Prospective, Single-Arm Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: The First Affiliated Hospital of Soochow University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if Dapagliflozin could prevent acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with haploidentical or unrelated donor and to assess its safety. The main questions it aims to answer are: Dose Dapagliflozin lower the cumulative incidence of aGVHD? What medical problems do participants undergoing allo-HCT from haploidentical or unrelated donor have when taking Dapagliflozin? Researchers will document the occurrence of graft-versus-host disease, hematopoietic reconstitution, survival rates and adverse effects. Participants will take Dapagliflozin every day in -1 to 14 days.

Conditions

• Graft-versus-host Disease (GVHD)

Interventions

Type	Name	Description
DRUG	Dapagliflozin (DAPA)	Participants will take Dapagliflozin 10mg every day in -1 to 14 days

Timeline

• Start date: 2025-04-26
• Primary completion: 2025-12-31
• Completion: 2026-12-31
• First posted: 2024-10-04
• Last updated: 2025-06-05

Locations

1 site across 1 country: China